This report provides in depth study of “ Women Healthcare Market 2017 Global Industry Research Report focuses on industry chain structure, market Size, Share, opportunities, future roadmap, industry analysis, industry policy analysis, market Leading player profiles and strategies. This New Report presented by Market Research Future contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Further MRFR asserts that the Market will demonstrate a colossal growth by 2023. Considering all these factors the global Women Healthcare market research report is projected to grow at a steady CAGR of 5.04% during the forecast period from 2017-2023.
Women Healthcare Market 2017 Global Industry Research Report focuses on industry chain structure, market Size, Share, opportunities, future roadmap, industry analysis, industry policy analysis, market Leading player profiles and strategies. This New Report presented by
Market Research Future contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Further
MRFR asserts that the Market will demonstrate a colossal growth by 2023. Considering all these factors the
global Women Healthcare market research report is projected to grow at a steady
CAGR of 5.04% during the forecast period from 2017-2023.
Market Research Future published new report, titled “Women Healthcare Market -Research Report: Global Forecast to 2023”.
Competition in the
Global Women Healthcare Market and are profiled in MRFR Analysis. “
Global Women Healthcare Market by Manufacturers, Countries, Type and Application, Forecast to 2023 Report “Provides In-Depth Analysis Of Parent Market Trends, Macro-Economic Indicators And Governing Factors Along With Market Attractiveness As Per Segments.
Allergan plc. (Ireland), Amgen (California), Bayer A G (Germany), Becton Dickinson and Company (U.S.), Eli Lilly Company (U.S.), Merck & Co., Inc., (U.S.), Pfizer Inc., (U.S.), Teva Pharmaceuticals (Israel), and others are some of the
Prominent Players at the forefront of competition in the
Global Women Healthcare Market and are profiled in MRFR Analysis.
Global Women Healthcare Market
Women health has been a concern from long period of time but past few years it has become an urgent priority for the whole world. Women’s health issues has now attracted the attention internationally. These concerns have taken the momentum rapidly when the United Nations’ has addressed the elimination of sex-based disparities in health care and reduction in maternal mortality in their Millennium Development Goals (MDG) by 2015.
Women’s lives have changed over the centuries, being a woman has many implications for health. Men and women share many similar health problems but some health problems are specific to women only. Women experience unique health issues and conditions from pregnancy and menopause to gynaecological conditions which affect the women’s health majorly. Many diseases occurred to women are caused due to poor health.
There are rising opportunities in the
women’s healthcare market in the near future due to the rising issues affecting women such as breast cancer, urinary tract infections, anaemia, a bone-related disorder, cardiovascular diseases and osteoporosis among others. The early diagnosis of the diseases provides an important opportunity in this market especially in developing nations where awareness of preventive care is on the rise. In response to this market, the healthcare industry is progressively employing early diagnosis through screening and monitoring of the women health disorders. For screening of these diseases, hospitals, and screening centres worldwide are digitizing systems to optimize workflows and enhance image clarity for providing accurate diagnosis of the disease.
Global Women Healthcare Market
– Competitive Analysis:
March, 2017- Eli Lilly announced phase 3 MONARCH 2 Breast Cancer Trial with a goal of bringing abemaciclib to patients with advanced breast cancer. The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer who have progressed after endocrine therapy. The results demonstrated the addition of abemaciclib to fulvestrant resulted in a statistically significant improvement in PFS (Progression-Free Survival), when compared to the control arm of placebo plus fulvestrant.
June 2016 – Merck (MSD) and Moderna have announced strategic collaboration to advance Novel mRNA-Based cancer vaccines with the help of Keytruda for the treatment of multiple types of cancer. This collaboration had established leadership in immuno-oncology with Moderna’s pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers. Moderna and Merck developed personalized cancer vaccines that utilize Moderna’s mRNA vaccine technology to encode a patient’s specific neoantigens, unique mutations present in that specific patient’s tumor. When injected into a patient, the vaccine will be designed to elicit a specific immune response that will recognize and destroy cancer cells.
September, 2016- Allergan and Richter had shown positive phase III results for Ulipristal acetate 5 and 10 mg in the treatment of uterine fibroids. Phase III study met all co-primary and secondary endpoints and achieved statistically significant results.
GET SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/3121 .
Global Women Healthcare Market
– Regional Analysis:
North America is the largest market which accounted for 39.1% in 2016 of the
global women healthcare market which is expected to grow at a CAGR of 4.5% during the forecast period. According to the Centers for Disease Control and Prevention (CDC) reports, in the U.S. approximately 12.5% of women older than 18 were considered to be in poor health in 2015. The rising prevalence of obesity is one of the key indicator which caused female specific health conditions. As per the World Health Organization (WHO), more than 1.9 billion adults aged 18 years and older were overweight and out of these over 600 million adults were obese ) in 2014. And this is the major cause of cardiovascular diseases, diabetes, musculoskeletal disorders, and some cancers such as endometrial, breast, ovarian among others. As per the study published in the journal JAMA reveals that for the years 2013-2014 the obesity prevalence was 35% for men and 40% for women in United States.
Major Table of Contents:
Chapter 1 Report Prologue
Chapter 2 Market Introduction
Chapter 3 Research Methodology
Chapter 4 Market Dynamics
Chapter 5 Market Factor Analysis
Chapter 6 Global Women Healthcare Market, By Indication
Chapter 7 Global Women Healthcare Market, By Diagnosis & Treatment
Chapter 8 Global Women Healthcare Market, By End User
Chapter 9 Global Women Healthcare Market, By Region
Chapter 10 Competitive Landscape
Chapter 11 Company Profile
Chapter 12 List of Tables
Table 1 Global Women Healthcare Market, By Indication, 2014-2023 (USD Million) 29
Table 2 Postmenopausal Osteoporosis Market, By Region, 2014-2023 (USD Million) 31
Table 3 Infertility Market, By Region, 2014-2023 (USD Million) 32
Table 4 Reproductive Health Management Market, By Region, 2014-2023 (USD Million) 33
Table 5 Polycystic Ovary Syndrome Market, By Region, 2014-2023 (USD Million) 34
Chapter 13 List of Figures
Figure 1 Global Women Healthcare Market: Market Structure 17
Figure 2 Research Process 18
Figure 3 Global Women Healthcare Market: Porters Five Forces Model 25
Figure 4 Global Women Healthcare Market: Value Chain Analysis 27
Figure 5 Global Women Healthcare Market, By Indication, 2016 & 2023 (USD Million) 30
GET DISCOUNT @ https://www.marketresearchfuture.com/check-discount/3121 .
About Market Research Future:
Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312
Source : https://www.medgadget.com/2017/12/women-healthcare-market-accretes-dramatically-with-a-whooping-cagr-of-5-04-by-2023-confirms-mrfr.html